Long-term clinical outcomes and stent thrombosis of sirolimus-eluting versus bare metal stents in patients with end-stage renal disease: results of Korean multicenter angioplasty team (KOMATE) Registry.
BACKGROUND
There are still controversies about long-term clinical outcomes of sirolimus-eluting stents (SES) versus bare metal stents (BMS) implantation in patients with end-stage renal diseases (ESRD).


OBJECTIVE
To compare long-term outcomes in patients with (ESRD) following SES versus BMS implantation.


METHODS
Between March 2003 and July 2005, a total of 54 patients (80 lesions) with ESRD undergoing SES implantation [SES-ESRD] were enrolled and compared with 51 patients (54 lesions) with ESRD receiving BMS during the same periods [BMS-ESRD] in the Korean Multicenter Angioplasty Team Registry. The primary outcome was the composite of death, myocardial infarction (MI), or any stent thrombosis (ST) according to the Academic Research Consortium definition during a 3-year follow-up.


RESULTS
The cumulative 3-year rate of composite of death, MI, or ST of the SES-ESRD group (24%) was nearly similar with that of the BMS-ESRD group (24%, P = 1.000). The 3-year rates of death (26% vs. 24%, P = 0.824) or MACE (37% vs. 43%, P = 0.331) in the SES-ESRD did not differ significantly from those in the BMS-ESRD. However, the SES-ESRD showed a sustained lower 3-year TVR rate (9%), compared with BMS-ESRD (24%, P = 0.042). The rate of any ST in SES-ESRD was not significantly higher than that in the BMS-ESRD (17% vs. 14%, P = 0.788). There was no significant difference in the rate of late or very late ST between SES-ESRD (15%) versus BMS-ESRD group (10%, P = 0.557).


CONCLUSIONS
SES did not increase the risks for death, MI, or any ST in patients with ESRD during the long-term follow-up, compared with BMS.
Kim
Byeong-Keuk
BK
Cardiology Division, Cardiovascular Center of National Health Insurance Corporation Ilsan Hospital, South Korea. kbk2565@freechal.com
Oh
Seungjin
S
Jeon
Dong Woon
DW
Yang
Joo Young
JY
Kim
Jung-Sun
JS
Park
Sungha
S
Choi
Donghoon
D
Jang
Yangsoo
Y
Hong
Bum-Kee
BK
Kwon
Hyuk Moon
HM
Lee
Seung-Whan
SW
Goh
Choong Won
CW
Kwon
Kihwan
K
Ryu
Sung Kee
SK
D000368:Aged; D015906:Angioplasty, Balloon, Coronary; D001807:Blood Vessel Prosthesis / Q000009:adverse effects; D019917:Blood Vessel Prosthesis Implantation / Q000009:adverse effects / Q000295:instrumentation / Q000379:methods; D003324:Coronary Artery Disease / Q000150:complications* / Q000401:mortality / Q000628:therapy*; D054855:Drug-Eluting Stents / Q000009:adverse effects*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage* / Q000009:adverse effects; D007676:Kidney Failure, Chronic / Q000150:complications*; D007723:Korea; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000209:etiology; D011474:Prosthesis Design; D011475:Prosthesis Failure; D012042:Registries; D012189:Retrospective Studies; D020123:Sirolimus / Q000008:administration & dosage* / Q000009:adverse effects; D015607:Stents / Q000009:adverse effects; D015996:Survival Rate; D013927:Thrombosis / Q000209:etiology*; D016896:Treatment Outcome
D007166:Immunosuppressive Agents; D020123:Sirolimus